The United States Food and Drug Administration (FDA) has granted fast track designation to United States-based Moderna for its investigational Zika vaccine, mRNA-1893, it was reported yesterday.
Presently, the mRNA-1893 vaccine is being evaluated in a phase one study to prevent Zika virus infection in healthy adults. The product included an mRNA sequence that encodes for the structural proteins of Zika virus. It is designed to help cells to secrete virus-like particles, helping to mimic the response of the cell after natural infection.
The phase 1 trial is evaluating the safety, pharmacokinetics and pharmacodynamics of the product in healthy volunteers. The company's randomised, observer-blind, placebo-controlled and dose-ranging study has been framed to evaluate the safety, tolerability and immunogenicity of mRNA-1893 in healthy flavivirus seropositive and seronegative adults aged between 18 and 49 years.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial